Alto Neuroscience Inc.
ANROAlto Neuroscience Inc. (ANRO) is a clinical-stage biotechnology company focused on developing precision neurology treatments. Leveraging advanced neurotechnology and data-driven insights, Alto aims to create personalized therapies for psychiatric and neurological disorders, including depression and anxiety, with an emphasis on improving patient outcomes through targeted interventions.
Company News
The psychedelic medicine sector is advancing with regulatory momentum, as the first psilocybin compound achieved two positive Phase 3 results in treatment-resistant depression. The DEA increased its 2026 psilocybin production quota by 67%. Five companies—Helus Pharma, Compass Pathways, Relmada Therapeutics, Alto Neuroscience, and Axsome Therape...
Law firm investigating potential claims against Alto Neuroscience after stock price dropped 69.99% following disappointing Phase 2b trial results for ALTO-100 depression treatment.
Levi & Korsinsky is notifying investors of a class action lawsuit against Alto Neuroscience regarding alleged securities fraud related to misleading statements about their product pipeline's effectiveness in treating major depressive disorder.
Rosen Law Firm alerts Alto Neuroscience investors about a securities class action lawsuit alleging false statements about the company's drug ALTO-100 and its effectiveness in treating major depressive disorder.
A class action lawsuit has been filed against Alto Neuroscience alleging misleading statements about their IPO and drug ALTO-100's effectiveness in treating major depressive disorder.
